The Anglo-Swedish pharmaceutical company will provide the European Commission with 90 million doses instead of the 180 initially agreed.
The pharmaceutical AstraZeneca plans to deliver to UnionEuropean half of the vaccines agreed for the second quarter of 2021, as reported by an official of the EU to Reuters. Thus, the Anglo-Swedish company will supply 90 million of doses instead of 180 million agreed for the months of April to June.
AstraZeneca’s contract with the European Commission, leaked to the media, showed that the pharmaceutical company had committed to delivering 180 million doses to 27 Member States during the second trimester.
But now it seems that everything has changed. It must be remembered that this reduction in the number of doses occurs after a large cutout in the forecasts for primertrimester.
“We are working to increase the productivity of our supply chain, both at a European and global level. We have the hope to be able to make our deliveries under the advance purchase agreement,” an AstraZeneca spokesman told Reuters.
In this way, the pharmaceutical company refuses to give details on specific figures and confirm whether it is true that the supply of vials will be reduced or not. The European Commission, which coordinates talks with vaccine manufacturers, has also refused to comment on this dose cut to the news agency.
AstraZeneca has already warned the EU that it would not meet its first quarter commitments due to “production problems”.
In fact, it was not the company’s first delay. In the last quarter of 2020, they promised to deliver 30 million doses. It is true that, in this case, it was not the responsibility of the pharmaceutical company. The vaccine had not yet been approved by Brussels.
Thus, AstraZeneca’s estimates of vaccines to the EU by the end of June would be about 130 million doses. far below the 300 million which he promised to deliver.
The EU has also faced delays in deliveries of vaccines developed by Pfizer Y BioNTechas well as the injection of Modern. So far, they are the only vaccines approved for use by the European Medicines Agency (EMA).